The impact of melatonin on the alleviation of cognitive impairment during electroconvulsive therapy: A double-blind controlled trial

Mostafa Hamdieh¹, Mohammad Abbasinazari²,³,⁴, Taleb Badri, Mohsen Saberi-Isefajani⁵, Gelareh Arzani⁶

¹ Psychosomatic Department, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
² Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
³ Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
⁴ Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
⁵ Medicine, Quran & Health Research Center & Department of Community Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Keywords:
Melatonin
Electroconvulsive therapy (ECT)
Cognition
Modified mental state examination (MMSE)

ABSTRACT

Background: The purpose of this study was to assess the efficacy and safety of melatonin in the prevention of cognitive impairments during ECT treatment.

Methods: Forty patients diagnosed with a major depressive disorder, for which ECT was indicated as a treatment for their current episode, were randomly allocated to either the melatonin (3 mg/day) group or the placebo group. The patients received melatonin or the placebo for the whole period of the ECT treatment, starting the day before ECT and continuing until the sixth session of ECT. The Modified Mental State Examination (MMSE) and item 3 MMSE were used for the assessment of cognition. Objective measures of cognitive functioning were performed pre-ECT and post-ECT.

Results: In both the MMSE score and item 3 MMSE, the melatonin group scored significantly higher at the end of the ECT sessions than the control group (P < 0.02, P = 0.001, respectively). None of the patients discontinued the melatonin or placebo due to side effects and there were no severe adverse drug reactions.

Conclusion: Although our data support the hypothesis that melatonin may reduce cognitive impairment following ECT, we believed that the findings provide an additional benchmark for further studies involving more patients.

1. Introduction

Electroconvulsive therapy (ECT) is the most effective acute treatment for severe depression, but widely held concerns regarding memory impairment may limit its use (Kirov et al., 2016). Most patients report some adverse cognitive effects during and after a course of ECT. A systematic review of four observational studies (597 patients treated with ECT) found that the proportion of patients who reported any memory loss ranged from 51 to 79 percent (Arevalo-Rodriguez, Smailagic et al., 2015). The incidence depends upon electrode placement, stimulus type and dose, anesthesia, and the patient’s pretreatment cognitive status (Matthews et al., 2013). Despite the large amount of literature on the neurobiology of therapeutic mechanisms of ECT, very little is known regarding the neurobiological underpinnings of its cognitive effects (Nobler & Sackeim, 2008). The neuroprotective effects of a number of pharmacological agents have been studied in previous animal and clinical studies. Most previous studies have evaluated anticholinesterase drugs to prevent or alleviate cognitive abnormality induced by ECT (Pigot, Andrade, & Loo, 2008). Other than cholinergic agents, Cyclo-Oxygenase 2 inhibitors, calcium channel blockers, nootropic agents, glucocorticoids and N-methyl-D-aspartate receptor antagonists have been tried for the alleviation of ECT-induced cognitive disorders (Abbasinazari, Adib-Eshgh et al., 2015). However, as yet, no pharmacological agent has been proven to consistently attenuate ECT-induced memory impairment.

Melatonin (N-acetyl-5-methoxytryptamine) is the main hormone synthesized by the pineal gland and is controlled by the suprachiasmatic nucleus(Waller et al., 2016). Melatonin and melatoninergic drugs have hypothetic effects mediated through two main receptors, namely MT1 and MT2 receptors, which act on the hypothalamic sleep switch. A beneficial effect of melatonin in neurodegenerative diseases has been reported in several studies (Carpentieri, D & az De Barboza, Areco, Peralta López, & Tolosa De Talamoni, 2012). A slight improvement in cognitive function was observed when melatonin was given to Alzhei-
mer’s Disease (AD) patients (Asayama et al., 2003). In addition, a retrospective study showed that melatonin treatment improved cognitive performance and sleep quality in patients with mild cognitive impairment (Furuya et al., 2012). Several neurodegenerative diseases, such as AD and Parkinson’s Disease (PD) are characterized by more irregular circadian rhythms and lower melatonin content than in age-matched controls (Waller et al., 2016). Also, patients with AD have a reduction in melatonin concentration, both in blood and cerebrospinal fluid, which is even present in early stages (Wu & Swaab, 2005). The aim of the present study was to evaluate the potential use of melatonin in the alleviation or prevention of cognition impairment in patients undergoing ECT. We were also interested in exploring the safety and tolerability of melatonin in patients receiving ECT.

2. Methods

2.1. Study design

This study was designed as a randomized, double-blind trial. The study setting was the psychiatry department of Taleghani Hospital, affiliated with Shahid Beheshti University of Medical Sciences, Tehran, Iran. This study was carried out in accordance with the most recent Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013). The study was reviewed and approved by the ethical committee of Shahid Beheshti University of Medical Sciences. Also, all the subjects signed consent forms after the study procedures were thoroughly explained. Trial was registered in Iranian clinical trial registry site with number IRCT201510324793N31. The criteria for inclusion in the study were a comprehensive psychiatric evaluation in which the patient met the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V) criteria for a major depressive disorder, for which ECT was indicated as a treatment for their current episode. All subjects received a comprehensive psychiatric evaluation and were given a diagnosis based on DSM-V criteria. Criteria for exclusion from the study were a history of schizophrenia, schizoaffective disorder, bipolar disorder I or II, or rapid cycling bipolar disorder. Patients with heart conduction dysfunction, bradyarrhythmia, liver or kidney disorders, or opioid dependency were also excluded from the study. Furthermore, medications such as cholinergic agents, COX-2 inhibitors, calcium channel blockers, nortropic agents, glucocorticoids or memantine were avoided before or during the study.

2.2. ECT protocols

ECT was performed using a square-wave, brief pulse, constant current device (MECTA 5000). The patients received melatonin or the placebo for the whole period of the ECT treatment, starting the day before ECT and continuing until the sixth session of ECT. As ECT was performed every other day in all participants, the duration between the first ECT and the sixth ECT was 12 days. Anaesthetic agents included propofol (AstraZeneca, England) at an average dose of 0.5–1 mg/kg, succinylcholine (Caspian, Iran) 20 mg and atropine (Alborzdaru, Iran) 0.5 mg. The placement of electrodes was right unilateral, following the standard D’Elia placement. For all subsequent treatments, stimulus intensity was maintained at 50–100% above the initial seizure threshold. A custom-modified MECTASR-1 was used for stimulus delivery. Vital signs were examined prior to and during the 5-min period following seizure termination. The stimulus frequency was 90 Hz and the stimulus duration ranged from 1 to 4 s. Seizure monitoring was performed using a two-lead electroencephalogram of the right and left hemispheres, as well as visual monitoring of residual motor convulsive activity.

2.3. Measures

The participants, who were admitted to receive ECT, were divided in either a melatonin or placebo group. We utilized an online statistical computing web program to randomize participant placement (www.graphpad.com/quickcalcs/randomize1.cfm). A student who was not involved in the volunteer recruitment classified patients into the melatonin or placebo group by using the mentioned web program. Opaque boxes were filled with either placebo or melatonin tablets and sealed and numbered to correspond to the web program generated sequence. All the patients had received ECT between 10–12 AM and the patients were asked to take memantine or placebo at around 8–9 P.M each night.

Demographic and hemodynamic parameters of eligible patients had been determined before enrolling on the study. Then, the participants were given 3 mg/day of melatonin or a placebo, beginning the day before the first session of ECT until the sixth session of ECT. A test to measure cognitive functioning, namely the Modified Mental State Examination (MMSE), was administered to patients both pre-ECT and post-ECT. Pre-ECT ratings were measured 24 h before the first ECT course, and post-ECT ratings were measured 24 h after the last ECT course. MMSE is well-known and the most often used short screening tool for providing an overall measure of cognitive impairment in clinical, research and community settings. The MMSE consists of 12 items and has a highest score of 30, with the score inversely related to cognitive abnormality. Traditionally, a 23/24 cut-off has been used to select patients with suspected cognitive impairment (Arevalo-Rodriguez, Smalilagic et al., 2015). Also, item 3 in the MMSE questionnaire on recent memory was used to assess the 2 groups. In item 3 of the MMSE, the examiner names three unrelated objects clearly and slowly, then asks the patient to repeat all three. The patient’s answer is used for scoring. The examiner repeats the names of the three objects until the patient learns all of them, if possible. The highest score is 3 and the lowest is 0 (Abbasinazari, Adib-Eshgh et al., 2015).

2.4. Statistical analysis

Data were analysed using the Statistical Package for the Social Sciences version 20 (SPSS-20), and P values less than 0.05 were considered statistically significant. Categorical data were analysed with chi-square statistics. The continuous data obtained in this study were analysed using a t-test or Mann–Whitney U test.

3. Results

Forty eligible patients (undergoing ECT therapy) completed the study. The mean age of the participants was 35.4 ± 12.9 and 52.5% of them was female. The flow of the participants through the study is shown in Fig. 1. Table 1 provides clinical variables for the melatonin and placebo groups. No significant group differences were noted for the initial level of cognitive functioning (MMSE and item 3 MMSE). There was no significant group difference in age between the two groups (p = 0.450). Also, the two groups had similar gender distributions; the melatonin group was 55% male and the placebo group was 40% male (p = 0.527). Also, no significant differences were noted for education level, domicile and duration of illness between the melatonin and placebo groups.

Table 2 provides the means for a number of ECT relevant variables. As Table 2 shows, there were no significant differences between the groups as regards systolic and diastolic blood pressure, heart rate and seizure time.

Fig. 2 summarizes the mean MMSE scores for the melatonin and placebo groups at the baseline and just end of the sixth course of ECT. Although the MMSE score was lower in the melatonin group compared with the placebo group at the baseline (p = 0.049), it had been raised significantly in the melatonin group compared with the placebo group after the sixth section of ECT (p < 0.001). Also, the melatonin group scored higher at the end of the sixth ECT session for MMSE and this was statistically significant (P < 0.001). In the placebo group, the MMSE
دریافت فوری
متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات